No Data
No Data
Dongyao Pharmaceutical - B (01875) revenue in the first three quarters increased by 49% year-on-year to 0.809 billion yuan.
Dongyao Pharmaceuticals - B (01875) announced that as of the nine months ended September 30, 2024, the Group's revenue...
Express News | TOT BIOPHARM International 9M Revenue RMB 809.021 Million
TOT BIOPHARM-B: INTERIM REPORT 2024
Dongyao Pharmaceuticals (1875.HK): CDMO project pool expands steadily, combining certainty and growth.
On August 7th, Hang Seng Index Company stated in an article that the biotech sector has shown signs of improvement recently, benefiting from policy support and a continuous inflow of funds over the past three months. With more policies being implemented, the Hang Seng Hong Kong-listed Biotech Index has outperformed the market since July. Clearly, the positive changes revealed in Hang Seng's article provide investors with a new perspective, which may also indicate a new turning point for the entire healthcare sector. In the current situation where the entire sector is still undervalued, as pharmaceutical companies enter the earnings season in the near future, it also brings a window of opportunity for the market to assess company value and predict future development. Recently, the interim report of the company was released.
TOT Biopharm International Turns to Profit in H1
Dongyang Pharmaceutical Company-B announced its mid-year performance. The net income for the first half of the year was RMB 31.559 million, a turned profit from a loss compared to the same period last year.
Dongyao Pharmaceutical-B (01875) released its six-month performance until June 30, 2024. The group obtained revenue of RMB 0.521 billion (unit in the following), a year-on-year increase of 58.69%. The company's equity holders' profit was RMB 31.559 million, compared with a loss of RMB 15.163 million in the same period last year, with a profit per share of RMB 0.04. Sales revenue of the product during the period was RMB 0.4004 billion, a year-on-year increase of 44%, mainly from the core product Bevacizumab Injection Poxin (PD-L1) with continued growth in sales. The income of CDMO/CMO business reached RMB 0.114 billion, a year-on-year increase of 144%, and the hematopoietic capacity was stable.
No Data
No Data